Author:
Sharma Bhawna,Crist Rachael M.,Adiseshaiah Pavan P.
Publisher
Springer Science and Business Media LLC
Reference93 articles.
1. Wang Y, Schmid-Bindert G, Zhou C. Erlotinib in the treatment of advanced non-small cell lung cancer: an update for clinicians. Ther Adv Med Oncol. 2012;4(1):19–29.
2. Wang JP, CY W, Yeh YC, Shyr YM, YY W, Kuo CY, et al. Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial. Oncotarget. 2015;6(20):18162–73.
3. Abramson R. Overview of targeted therapies for cancer. 2017 [updated August 1, 2017. Available from: https://www.mycancergenome.org/content/molecular-medicine/overview-of-targeted-therapies-for-cancer/ .
4. Maher M. Current and emerging treatment regimens for HER2-positive breast cancer. P T. 2014;39(3):206–12.
5. Kim ST, Lim DH, Jang KT, Lim T, Lee J, Choi YL, et al. Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy. Mol Cancer Ther. 2011;10(10):1993–9.
Cited by
10 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献